Focal Intraoperative Radiotherapy of Brain Metastases
Primary Purpose
Brain Metastases, Adult, Central Nervous System Metastases
Status
Terminated
Phase
Phase 2
Locations
Brazil
Study Type
Interventional
Intervention
Intraoperative Radiotherapy
Sponsored by
About this trial
This is an interventional treatment trial for Brain Metastases, Adult focused on measuring Intraoperative Radiotherapy
Eligibility Criteria
Inclusion Criteria:
- Age >18 years
- Histologically confirmed diagnosis of invasive cancer in the presence of up to 10 lesions suggestive of BM
- Indication of resection of single lesion suggestive of BM and evidence of macroscopic complete resection
- Patient consent to participate in the study
Exclusion Criteria:
- Previous cranial radiotherapy
- Any kind of antineoplasic systemic treatment for less than 7 days of the procedure
- Cavities with proximity < 10 mm from the brainstem or optical pathway.
- Pregnant patients
Sites / Locations
- AC Camargo Cancer Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Intraoperative Radiotherapy
Arm Description
Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG)
Outcomes
Primary Outcome Measures
Local control (LC)
Rate of local failure in the surgical cavity
Control of Brain Disease (CBD)
Rate of control in the brain outside
Secondary Outcome Measures
Overall Survival (OS)
Rate of death related to any cause
Frequency of radiation necrosis
Imaging evaluation
Full Information
NCT ID
NCT03789149
First Posted
December 26, 2018
Last Updated
July 24, 2023
Sponsor
AC Camargo Cancer Center
Collaborators
Carl Zeiss Meditec AG
1. Study Identification
Unique Protocol Identification Number
NCT03789149
Brief Title
Focal Intraoperative Radiotherapy of Brain Metastases
Official Title
Focal Intraoperative Radiotherapy After Resection of Brain Metastases
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Terminated
Why Stopped
Planning to join a prospective multicentric trial after evaluation of 10 first participants
Study Start Date
May 2, 2019 (Actual)
Primary Completion Date
June 30, 2022 (Actual)
Study Completion Date
June 30, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AC Camargo Cancer Center
Collaborators
Carl Zeiss Meditec AG
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Brain metastases (BM) are the most prevalent tumors of the central nervous system (CNS), with a ratio of 10: 1 in relation to primary tumors. In prospective studies, whole-brain radiotherapy (WBRT) reduced the risk of local recurrence after resection of brain metastases from 46-59% to 10-28%. Furthermore, WBRT reduces the incidence of new metastases and death from disease, but no apparent improvement in overall survival (OS). Due to the potential neurocognitive effects associated with WBRT compared to isolated focal approach, several authors have suggested delaying WBRT and perform focal adjuvant RT after resection of isolated BM. In this context, intraoperative radiotherapy (IORT) in the cavity after resection of BM may be an appealing option.
The primary objectives of this study are to evaluate local control (LC) and the control of brain disease (LC associated with the absence of new distant BM) after IORT for one completely resected supratentorial BM in the presence of up to 10 lesions suggestive of BM.
Detailed Description
Brain metastases (BM) are the most prevalent tumors of the central nervous system (CNS), with a ratio of 10: 1 in relation to primary tumors. This type of metastasis occurs in 20-40% of cancer patients and are related to significant morbidity and mortality.
In prospective studies, whole-brain radiotherapy (WBRT) reduced the risk of local recurrence after resection of brain metastases from 46-59% to 10-28%. Furthermore, WBRT reduces the incidence of new metastases and death from disease, but no apparent improvement in overall survival (OS). Due to the potential neurocognitive effects associated with WBRT compared to isolated focal approach, several authors have suggested delaying WBRT and perform focal adjuvant RT after resection of isolated BM.
The utilization of intraoperative radiotherapy (IORT) in the cavity after resection of primary or BM has been described in the literature, the majority of reports describes performing brachytherapy with iodine seeds or interstitial radiosurgery. However, there is a paucity of information regarding the use of IORT with low energy X-ray for focal treatment after resection of brain BM.
The objectives of this study are evaluate local control (LC), the control of brain disease in patients with metastatic brain disease (up to 10 lesions) submitted to focal IORT to an isolated surgical cavity, evaluate overall survival (OS), evaluate the frequency of radiation necrosis and correlate the prognostic factors related to the patient with OS and the parameters of the treatment (dose, volume, lesion location) with the LC and radiation necrosis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Brain Metastases, Adult, Central Nervous System Metastases
Keywords
Intraoperative Radiotherapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
Single group assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intraoperative Radiotherapy
Arm Type
Experimental
Arm Description
Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG)
Intervention Type
Radiation
Intervention Name(s)
Intraoperative Radiotherapy
Other Intervention Name(s)
Intrabeam
Intervention Description
Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG) consisting of a small source of low energy x-rays (30-50 kV) mounted on a mechanical arm with six degrees of freedom. The resulting dose distribution is isotropic around the tip of the X-ray source. A set of spherical applicators with diameters ranging from 1.5 to 5 cm is available to connect to the source. The treatment time may vary from 20-30 minutes with the suggested dose of 18 Gy to the resection cavity to a depth of 1 mm.
Primary Outcome Measure Information:
Title
Local control (LC)
Description
Rate of local failure in the surgical cavity
Time Frame
1 year
Title
Control of Brain Disease (CBD)
Description
Rate of control in the brain outside
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Overall Survival (OS)
Description
Rate of death related to any cause
Time Frame
1 year
Title
Frequency of radiation necrosis
Description
Imaging evaluation
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age >18 years
Histologically confirmed diagnosis of invasive cancer in the presence of up to 10 lesions suggestive of BM
Indication of resection of single lesion suggestive of BM and evidence of macroscopic complete resection
Patient consent to participate in the study
Exclusion Criteria:
Previous cranial radiotherapy
Any kind of antineoplasic systemic treatment for less than 7 days of the procedure
Cavities with proximity < 10 mm from the brainstem or optical pathway.
Pregnant patients
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Douglas G Castro, MD
Organizational Affiliation
AC Camargo Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
AC Camargo Cancer Center
City
São Paulo
State/Province
SP
ZIP/Postal Code
01509-900
Country
Brazil
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Time Frame
6 months after publication
IPD Sharing Access Criteria
Correlated Area Investigators with publishing background and a defined objective
Learn more about this trial
Focal Intraoperative Radiotherapy of Brain Metastases
We'll reach out to this number within 24 hrs